CDKN2A and neoplasm: Similarly, CDKN2A-MUT or DEL patients had lower expression of critical immune function genes in most tumor types, which could influence immune regulators in the tumor microenvironment, such as immunoinhibitory molecules, immune stimulators, MHC molecules, chemokines, and chemokine receptors, than CDKN2A-WT patients (Fig. 6B, Figure S5 A and B).